Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry

Immunohistochemistry results for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are used to guide breast carcinoma patient management and it is essential to monitor these tests in external quality assurance (EQA) programs. Canadian Immunohistochemistry Quality Control is a web-based program with novel approach to EQA. Canadian Immunohistochemistry Quality Control RUN2 included tissue microarray slides with 38 samples tested by 18 immunohistochemical laboratories. Deidentified results were posted for viewing at www.ciqc.ca including all used protocols matched with scanned slides for virtual microscopy and garrattograms. Sensitivity, specificity, Kendall W test (concordance between laboratories), and κ statistics (agreement with designated reference values) were calculated. Kappa values were within the target range (>0.8, or “near perfect” agreement) for 85% results. Kendall coefficient was 0.942 for estrogen receptor, 0.930 for progesterone receptor, and 0.958 for human epidermal growth factor receptor 2. The anonymous participation, quick feedback, and unrestricted full access in EQA results provides rapid insight into technical or interpretive deficiencies, allowing appropriate corrective action to be taken whereas the use of tissue microarrays enables meaningful statistical analysis.

[1]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[2]  Mark Quinn.  Newfoundland launches judicial inquiry , 2007, Canadian Medical Association Journal.

[3]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[4]  James N Ingle,et al.  HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.

[5]  D. Rimm,et al.  Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.

[6]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[7]  F. O'Malley,et al.  Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer , 2007, Current oncology.

[8]  P. Klein,et al.  Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.

[9]  P. Regitnig,et al.  Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories , 2002, Virchows Archiv.

[10]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[12]  Peter A Kaufman,et al.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Christensen,et al.  Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables , 2008, Acta oncologica.

[14]  G. Francis,et al.  Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program , 2007, Journal of Clinical Pathology.

[15]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[16]  J. Peterse,et al.  Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study , 2004, Virchows Archiv.

[17]  L. Bobrow,et al.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[19]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.